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EDITORIAL
Cardiorespiratory Fitness in Patients with Advanced
Non-small Cell Lung Cancer
Why is this Feature Important to Evaluate? Can it be Improved?
Jean Louis Pujol, MD, Xavier Quantin, MD, and Mohammad Chakra, MD
Patients suffering from non-small cell lung cancer (NSCLC) are frequently affected bya high level of symptom burden.1 Consequently, these patients also have a poor quality
of life, insofar as symptom score is one of the five dimensions of quality of life (aside,
functional, psychologic, social, and spiritual dimensions2). A high symptom score, by
itself might require specific interventions, palliation or supportive therapies to achieve
symptoms alleviation. Consequences of a high symptom score could be regarded from two
major points of view. (i) some symptoms can indicate a severe patient disability and
therefore might modify anticancer treatment program by limiting indication for some
important treatment modalities such as surgery. (ii) high symptom score is reducing
patient ability to achieve a normal familial and social activity. This interference between
symptoms score and social life, referred to as global health status in quality of life scale,
has been demonstrated as indicating a poor outcome.3
Among the most frequently observed symptoms in NSCLC, two could be regarded as
directly involved in reducing patient daily activity living: dyspnoea and fatigue. Both
symptoms have major impact in cardiopulmonary fitness on exercise. Studies that aim at
measuring cardiopulmonary fitness in NSCLC might therefore be regarded as a global
investigation exploring main host-tumor relationship features that could have major impact in
both treatment decision and quality of life.4 Conversely, studies that aim at improving
cardiopulmonary fitness on exercise might be considered as interesting approaches at improv-
ing quality of life. In this issue of the journal, Kasymjanova et al.5 presented a noninterven-
tional study evaluating exercise capacity in patients with newly diagnosed advanced NSCLC
and its relationship with survival. Temel et al.,6 also in this issue report an interventional study
performed in an effort at improving functional outcome and symptoms in a similar advanced
NSCLC population by mean of a structured exercise program. In this brief editorial we would
like to summarize and comment on results of both studies by highlighting three different
issues: (1) methodological aspects of the evaluation of cardiopulmonary fitness in oncologic
patients; (2) multidimensional aspect of fatigue and dyspnoea in patients receiving treatment
for advanced NSCLC; and (3) meaning of the evaluation and intervention on cardiopulmonary
fitness for these patients in daily practice.
Briefly, in the study by Kasymjanova et al., patients receiving chemotherapy for a
NSCLC have underwent repeated evaluation by exercise tests (by means of the submaxi-
mum 6-minute walk test [6MW]): One before chemotherapy (preceded by a training test)
and the second after the second cycle of chemotherapy. The main findings are as follows:
a poor performance during the prestudy 6MW test (6MW 400 m) at presentation by
itself, is an independent unfavorable prognostic factor; patients who did not achieve the
complete program (but were only able to perform the prestudy test) were at higher risk of
death. Among patients who completed both pre- and posttreatment 6MW tests, patients for
whom performance on exercise had decreased, were at higher risk of disease progression
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when compared with patients with stable performance. The
study by Temel et al. has dealt with possible quality of life
improvement and symptom alleviation in advanced NSCLC
patients who have underwent an exercise program. The au-
thors have constructed a twice-weekly exercise program per-
formed in their medical unit on an out-patient basis. The
program has been adapted to the demography and specifici-
ties of patients suffering from inoperable NSCLC who un-
derwent chemotherapy, in parallel to the exercise program. A
total of 16 training sessions were planned. The feasibility of
the program is not demonstrated by itself inasmuch as, only
41% of patients achieved the whole program. Nevertheless,
the patients had completed it, experienced a significant re-
duction in lung cancer symptoms and no deterioration in their
6MW test or muscle strength.
First, we should address the methodology of cardiorespi-
ratory fitness testing. Cardiorespiratory fitness is determinant in
patients who are planned for major surgical resection for lung
cancer.7 The optimal means to assess cardiorespiratory fitness is
an incremental cardiopulmonary exercise test (CPET) to exhaus-
tion or symptom limitation. This test requires complex equip-
ments, rigorous methodology in standardizing and monitoring
the maximal exercise test. According to the American Thoracic
Society/American College of Chest Physicians recommenda-
tions,8 up to 10 different parameters might be analyzed, among
them the more useful are respiratory exchange ratio, maximum
oxygen consumption at peak, heart rate, and oxygen pulse. All
these parameters are critical when the primary goal of the CPET
is to determine whether or not a patient with compromised
cardiorespiratory fitness, will be able to undergo major pulmo-
nary resection. However, complexity of maximum CPET limits
its use in other settings than presurgical work-up, such as
evaluation of exercise limitation in patients with otherwise
resectable NSCLC. Submaximum testing (without gas-exchange
measurement) such as the 6MW test, might be appropriate for
patients who are frail or elderly, or with heavy disease burden
that compromised the completion of a maximum CPET, such as
it is the case in most patients suffering from advanced NSCLC.
However, the interpretation might be with caution, as submaxi-
mum testing relies on an extrapolation of cardiorespiratory
fitness from submaximum work rate. The two main reported
results of the 6MW are heart rate and covered distance. This
latter important parameter depends on normative data taking into
account different patients characteristics including age. In pa-
tients affected by cancer who underwent chemotherapy, it is
possible that autonomic dysfunctions that modify heart rate are
emphasized in comparison with other categories of patients.
Nonetheless, 6MW test is inexpensive, safe, and can be repro-
duced easily.9 In addition, several studies have demonstrated
that the distance covered is a robust and strength result that could
be regarded as an independent prognostic determinant in various
disorders such as chronic heart failure or chronic obstructive
pulmonary disease. The study by Kasymjanova et al. similarly
demonstrated a relationship between distance covered and sur-
vival in advanced NSCLC. We must acknowledge the authors
for this important observation. Some limitations of this study
would warrant further investigations, however. One can hypoth-
esize that a confirmatory study performed in a larger population
would be able to take into account the multidimensional feature
of cardiorespiratory unfitness in patients with lung cancer.
Secondly, there are multidimensional aspects of fatigue
and dyspnoea. Cardiorespiratory unfitness in NSCLC has been
demonstrated to depend on many different factors. Incidence of
important comorbid conditions such as coronary artery disease,
heart failure, and chronic obstructive pulmonary disease are
quite common in this disease. Interaction between disease and
comorbidity in cardiorespiratory fitness are important compo-
nents explaining poor performance on maximum CPET such as
the one observed in patients with preexisting compromised
respiratory function and suffering from otherwise resectable
NSCLC. The pulmonary function impairment frequently ob-
served in patients affected by a more advanced disease (locally
advanced or metastatic), might frequently result in poor cardio-
vascular fitness. Frequency of this deconditioning is higher when
compared with that observed in localized NSCLC patients. As
simple indicators, 56% of patients with advanced NSCLC
present with dyspnoea on exercise and 79% complain from
fatigue. The different factors reducing cardiorespiratory fitness
in advanced NSCLC can be classified in three different catego-
ries: first, those directly related to the disease such as cough,
bronchial obstruction, pulmonary volume limitation due to pleu-
ral effusion, etc. In addition, lung cancer-induced cytokine
productions such as tumor-necrosis-factor-, might also induce
weight loss and muscle weaknesses as a consequence of ca-
chexia. Second, comorbidities, as aforementioned, particularly,
those comorbid conditions related to tobacco consumption,
mainly chronic obstructive pulmonary disease, may be the major
limiting factor limiting exercise. An important proportion of
patients with advanced lung cancer have history of several
decades of dyspnoea on exercise previous to cancer diagnosis.
Third, and perhaps most importantly, there are many treatment-
related factors that might interact with the ability for a given
patient to complete an exercise test. Among them, one can
consider the following: chemotherapy-induced anemia, chemo-
therapy-induced neuropathy and muscle disease, radiotherapy
induced-pneumonitis, chemotherapy agents- or gefitinib-in-
duced interstitial lung disease. In our opinion, these factors that
putatively interfere with cardiorespiratory fitness might be taken
into account when interpreting a decrease in distance covered by
a patient, when two different 6MW tests are performed at the
beginning and during a medical treatment for cancer.
The last question deals with the meaning of cardiopul-
monary fitness for these patients daily practice. As clearly
demonstrated by the noninterventional Kasymjanova’s study,
patients with poor performance on exercise are at higher risk
of death and disease progression. Although, this observation
could not take into account the multidimensional aspect of the
lack of cardiorespiratory fitness, the results reported here is
an additional clue that patients with poor quality of life at
presentation also have a poor prognosis when compared with
patients with a good global health status at presentation. The
study by Temlet et al. clearly suggested that this is change-
able and that an adapted exercise program can improve ability
to perform exercise for some patients. Further investigations
in this field are warranted in consideration of the true alter-
ation of patient quality of life related to dyspnoea and fatigue.
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